AU2005314788B2 — Amide compound and thrombopoietin receptor activator
Assigned to Nissan Chemical Corp · Expires 2011-09-22 · 15y expired
What this patent protects
A compound effective in the prevention, treatment, or alleviation of diseases in which thrombopoietin receptor activation is effective. It is a compound represented by the formula (1) (wherein A, B, R, L, R, L, L, Y, L, R, and X are as defined in the description), a tautomer or p…
USPTO Abstract
A compound effective in the prevention, treatment, or alleviation of diseases in which thrombopoietin receptor activation is effective. It is a compound represented by the formula (1) (wherein A, B, R, L, R, L, L, Y, L, R, and X are as defined in the description), a tautomer or prodrug of the compound, a pharmaceutically acceptable salt of either, or a solvate of these. (1)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.